SPIRITS
Regimen
- Experimental
- S-1 + cisplatin 60 mg/m2 Q5W
- Control
- S-1 monotherapy
Population
Japanese patients with advanced gastric cancer receiving first-line therapy
Key finding
mOS 13.0 vs 11.0 mo (HR 0.77, 95% CI 0.61-0.98, p=0.04); mPFS 6.0 vs 4.0 mo (HR 0.57); ORR 54% vs 31%
Source: PMID 18282805
Timeline
Guideline citations
- CSCO GASTRIC 2025 (p.109)⚠️ OCR source